110. Synthetic lethality for linking Mycophenolate Mofetil mode of action with molecular disease and drug profiles. Mol Biosyst. 2012; 8(12):3197-3207. (IF 3.336)

Söllner J, Mayer P, Heinzel A, Fechete R, Siehs C, Oberbauer R, Mayer B.

109. Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters. PLOS ONE 2012;7(7):e39229. (IF 2.9)

Haller M, Amatschek S, Wilflingseder J, Kainz A, Bielesz B, Pavik I, Serra A, Mohebbi N, Biber J, Wagner CA, Oberbauer R.

108. Molecular pathways and crosstalk characterizing the cardiorenal syndrome. OMICS 2012; 16(3):105-112. (IF 3.3)

Mühlberger I, Mönks K, Fechete R, Mayer G, Oberbauer R, Mayer B, Perco P.

107. Data graphs for linking clinical phenotype and molecular feature space. IJSBBT 2012; 1(1):11-25.

Heinzel A, Fechete R, Söllner J, Perco P, Heinze G, Oberbauer R, Mayer G, Lukas A, Mayer B.

106. Hemoglobin variability after renal transplantation is associated with mortality. Transpl Int 2012; 25(3):323-327. (IF 2.7)

Kainz A, Wilflingseder J, Függer R, Kramar R, Oberbauer R.

105. The effect of steroid pretreatment of deceased organ donors on liver allograft function: a blinded randomized placebo controlled trial. J Hepatol 2012; 56(6):1305-1309. (IF 26.8)

Amatschek S, Wilflingseder J, Pones M, Kainz A, Bodingbauer M, Mühlbacher F, Langer RM, Gerlei Z, Oberbauer R.

SCIENTIFIC COLLABORATIONS